Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

October 25, 2022 08:00 ET | Source: InspireMD, Inc.

InspireMD to Report Third Quarter 2022 Financial Results on November 8, 2022, and Provide Corporate Business Update

TEL AVIV, Israel, Oct. 25, 2022 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard™ Embolic Prevention Stent System (EPS) device for the treatment of Carotid Artery Disease...
June 25, 2020 10:00 ET | Source: InspireMD, Inc.

InspireMD Announces Late-Breaking Presentation of Early SIBERIA Clinical Trial Results to be Featured in an e-Course at EuroPCR

TEL AVIV, Israel, June 25, 2020 (GLOBE NEWSWIRE) -- InspireMD, Inc. (NYSE American: NSPR), developer of the CGuard™ Embolic Prevention System (EPS) for the prevention of stroke caused by carotid...
June 10, 2020 08:00 ET | Source: InspireMD, Inc.

InspireMD Announces Publication of 12-Month Results of CGuard™ EPS PARADIGM Trial in EuroIntervention

Results indicate that 12 months after carotid intervention the CGuard EPS MicroNET-covered stent delivers sustained protection against postprocedural neurologic events TEL AVIV, Israel, June 10,...
June 08, 2020 08:00 ET | Source: InspireMD, Inc.

InspireMD, Inc. Announces Underwriter Exercise of Over-Allotment Option in Full and Closing of $11.5 Million Follow-On Underwritten Public Offering

TEL AVIV, Israel, June 08, 2020 (GLOBE NEWSWIRE) -- InspireMD, Inc. (NYSE American: NSPR), the developer of the CGuard™ Embolic Prevention System (EPS) for the prevention of stroke caused by...
June 03, 2020 07:40 ET | Source: InspireMD, Inc.

InspireMD, Inc. Announces Pricing of $10 Million Underwritten Public Offering

TEL AVIV, Israel, June 03, 2020 (GLOBE NEWSWIRE) -- InspireMD, Inc. (NYSE American: NSPR), the developer of the CGuard™ Embolic Prevention System (EPS) for the prevention of stroke caused by carotid...
May 12, 2020 07:00 ET | Source: InspireMD, Inc.

InspireMD Announces First Quarter 2020 Financial Results

First quarter revenue growth driven by continued strong uptake of the CGuard™ Embolic Prevention System (EPS) in the company’s major markets Management to host investor conference call today,...
May 05, 2020 08:00 ET | Source: InspireMD, Inc.

InspireMD to Report First Quarter 2020 Financial Results and Provide Business Update on Tuesday, May 12

TEL AVIV, Israel, May 05, 2020 (GLOBE NEWSWIRE) -- InspireMD, Inc. (NYSE American: NSPR), developer of the CGuard™ Embolic Prevention System (EPS) for the prevention of stroke caused by carotid...
March 10, 2020 08:00 ET | Source: InspireMD, Inc.

InspireMD Announces Fourth Quarter and Year-End 2019 Financial Results

Robust CGuard™ EPS year-over-year revenue growth of 31% Management to host investor conference call today, March 10, at 8:30am ET TEL AVIV, Israel, March 10, 2020 (GLOBE NEWSWIRE) -- InspireMD,...
March 03, 2020 08:00 ET | Source: InspireMD, Inc.

InspireMD to Report Fourth Quarter 2019 Financial Results and Provide Business Update on Tuesday, March 10

TEL AVIV, Israel, March 03, 2020 (GLOBE NEWSWIRE) -- InspireMD, Inc. (NYSE American: NSPR), developer of the CGuard™ Embolic Prevention System (EPS) for the prevention of stroke caused by carotid...
January 29, 2020 08:00 ET | Source: InspireMD, Inc.

InspireMD Announces Successful Live Clinical Case Transmissions Featuring CGuard™ EPS at the Leipzig Interventional Course (LINC) 2020

TEL AVIV, Israel, Jan. 29, 2020 (GLOBE NEWSWIRE) -- InspireMD, Inc. (NYSE American: NSPR), developer of the CGuard™ Embolic Prevention System (EPS) for the prevention of stroke caused by carotid...

keyboard_arrow_left Previous Page

Next Page keyboard_arrow_right